Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Chief Scientific Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 986,117 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 1,673 · Balance 986,117 F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2024 Filed Jul 30, 2024 20:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,154 | $23.66 | $27,303.64 |
DisclosureSEC source: 0000950170-24-087889 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925,234 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:56 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 268 | $20.65 | $5,534.20 |
DisclosureSEC source: 0000950170-24-068791 · ownership.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926,388 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:56 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 714 | $20.65 | $14,744.10 |
DisclosureSEC source: 0000950170-24-068791 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926,656 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 362 | $21.14 | $7,652.68 |
DisclosureSEC source: 0000950170-24-065236 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,370 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:35 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 79 | $20.35 | $1,607.65 |
DisclosureSEC source: 0000950170-24-052222 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,732 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 20:02 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,154 | $20.10 | $23,195.40 |
DisclosureSEC source: 0000950170-24-050506 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,811 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 268 | $23.24 | $6,228.32 |
DisclosureSEC source: 0000950170-24-026004 · ownership.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 928,965 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 704 | $23.24 | $16,360.96 |
DisclosureSEC source: 0000950170-24-026004 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,233 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 21,146 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022468 · ownership.xml · nonDerivative · entry 5 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,937 F5 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 26, 2024, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,888 | $24.26 | $45,802.88 |
DisclosureSEC source: 0000950170-24-022468 · ownership.xml · nonDerivative · entry 4 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 908,791 F4 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,402 | $24.26 | $34,012.52 |
DisclosureSEC source: 0000950170-24-022468 · ownership.xml · nonDerivative · entry 3 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 910,679 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 5,304 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022468 · ownership.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,081 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 3,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022468 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 906,777 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:50 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,617 | $24.06 | $38,905.02 |
DisclosureSEC source: 0000950170-24-021517 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 902,850 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:39 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 90 | $25.00 | $2,250.00 |
DisclosureSEC source: 0000950170-24-009853 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 904,467 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,325 | $25.60 | $33,920.00 |
DisclosureSEC source: 0000950170-24-008854 · ownership.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 904,557 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November, 9 2022. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 22:47 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,437 | $27.57 | $39,622.69 |
DisclosureSEC source: 0001209191-23-057662 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905,882 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $27.25 to $27.79, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 21:38 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 109 | $23.64 | $2,576.76 |
DisclosureSEC source: 0001209191-23-054046 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 907,319 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 21:24 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 5,504 | $24.03 | $132,233.60 |
DisclosureSEC source: 0001209191-23-053870 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 907,428 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units held by the reporting person and assumed by the Issuer on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 20:34 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,041 | $31.41 | $32,695.62 |
DisclosureSEC source: 0001209191-23-048930 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,932 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $31.345 to $31.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:34 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 342 | $33.88 | $11,587.34 |
DisclosureSEC source: 0001209191-23-046712 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 913,973 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $33.55 to $34.19, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 21:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 76 | $38.63 | $2,935.88 |
DisclosureSEC source: 0001209191-23-044023 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,315 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,000 | $40.30 | $40,296.10 |
DisclosureSEC source: 0001209191-23-034790 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,391 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $39.79 to $40.75, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:15 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 345 | $35.46 | $12,234.49 |
DisclosureSEC source: 0001209191-23-030994 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,391 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $34.96 to $36.15, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 30, 2023 Filed May 2, 2023 20:59 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 76 | $29.57 | $2,247.32 |
DisclosureSEC source: 0001209191-23-026560 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,736 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,804 | $31.85 | $121,157.40 |
DisclosureSEC source: 0001209191-23-015514 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,812 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 794 | $31.65 | $25,130.10 |
DisclosureSEC source: 0001209191-23-013280 · doc4.xml · nonDerivative · entry 3 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919,616 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 12,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013280 · doc4.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,410 F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 23, 2023, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 2,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013280 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,254 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 383 | $33.99 | $13,018.17 |
DisclosureSEC source: 0001209191-23-010727 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,112 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 23:13 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 90 | $33.04 | $2,973.60 |
DisclosureSEC source: 0001209191-23-005984 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,495 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 342 | $35.89 | $12,274.59 |
DisclosureSEC source: 0001209191-22-057840 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,585 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 02:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 51,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056316 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,927 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger (the "Effective Time"), each award of restricted stock units ("RSUs") based on Fulgent Pharma common stock that was outstanding immediately prior to the Effective Time ("Fulgent Pharma RSUs") was assumed and converted into the right to receive RSUs based on the common stock of Fulgent Genetics with the same terms and conditions as the Fulgent Pharma RSUs immediately prior to the Effective Time, subject to the applicable exchange ratio. F2 · kind: (continued from footnote 1) Twenty-five percent (25%) of the shares subject to RSUs reported herein will vest on the first anniversary of the date of the award, October 26, 2022, and 1/16th of the shares will vest every three months over the remaining 36-month period, subject to continued service for Issuer on each vesting date. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 21:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 76 | $40.28 | $3,061.28 |
DisclosureSEC source: 0001209191-22-055074 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,204 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 21:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 370 | $48.89 | $18,090.97 |
DisclosureSEC source: 0001209191-22-046866 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,280 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $48.67 to $49.02, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 30, 2022 Filed Aug 2, 2022 20:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 87 | $59.75 | $5,198.25 |
DisclosureSEC source: 0001209191-22-043871 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,650 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:37 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 325 | $53.38 | $17,349.25 |
DisclosureSEC source: 0001209191-22-030061 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,737 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $53.27 to $53.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 30, 2022 Filed May 3, 2022 21:15 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 283 | $54.88 | $15,531.04 |
DisclosureSEC source: 0001209191-22-026808 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,062 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014738 · doc4.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,345 F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after March 1, 2022, and 1/16th of such shares vesting at the end of every three-month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014738 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,345 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2022, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 303 | $66.49 | $20,146.47 |
DisclosureSEC source: 0001209191-22-010875 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,345 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:58 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 311 | $95.50 | $29,701.15 |
DisclosureSEC source: 0001209191-21-065504 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,648 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $95.3400 to $95.6200, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:54 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 314 | $95.12 | $29,868.53 |
DisclosureSEC source: 0001209191-21-052299 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,959 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $94.6257 to $96.0400, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 315 | $70.71 | $22,273.71 |
DisclosureSEC source: 0001209191-21-034515 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,273 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $69.61 to $71.05, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 30, 2021 Filed May 3, 2021 20:43 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029476 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,588 F1 · shares: Reflects an award of restricted stock units relating to 3,500 shares of the Issuer's common stock. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after April 30, 2021, and 1/16th of such shares vesting every three months over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| February 15, 2021 Filed Feb 16, 2021 23:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 303 | $161.09 | $48,810.27 |
DisclosureSEC source: 0001209191-21-010925 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,088 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 00:50 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 301 | $45.45 | $13,680.09 |
DisclosureSEC source: 0001209191-20-059269 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,391 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $45.2512 to $45.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 00:52 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | OtherCommon Stock | 467,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050606 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,692 F1 · kind: The transfer was made without the receipt of consideration to a blind trust. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| August 17, 2020 Filed Aug 20, 2020 01:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,308 | $41.11 | $53,771.62 |
DisclosureSEC source: 0001209191-20-047659 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,351 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $41.10 to $41.11, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 12, 2019 Filed Sep 17, 2019 01:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | OtherIssuer Common Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049726 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,267,659 F1 · kind: The transfer was made without the receipt of consideration to a blind trust. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.